Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria

Abstract

BackgroundDespite reports of hematuria and proteinuria with rosuvastatin use at the time of its approval by the US Food and Drug Association (FDA), little postmarketing surveillance exists to assess real-world risk. Current labeling suggests dose reduction (maximum daily dose of 10 mg) for patients with severe CKD.MethodsUsing deidentified electronic health record data, we analyzed 152,101 and 795,799 new users of rosuvastatin and atorvastatin, respectively, from 2011 to 2019. We estimated inverse probability of treatment–weighted hazard ratios (HRs) of hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) associated with rosuvastatin. We reported the initial rosuvastatin dose across eGFR categories and evaluated for a dose effect on hematuria and proteinuria.ResultsOverall, we identified 2.9% of patients with hematuria and 1.0% with proteinuria during a median follow-up of 3.1 years. Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria (HR, 1.08; 95% confidence interval [95% CI], 1.04 to 1.11), proteinuria (HR, 1.17; 95% CI, 1.10 to 1.25), and KFRT (HR, 1.15; 95% CI, 1.02 to 1.30). A substantial share (44%) of patients with eGFR <30 ml/min per 1.73 m2 was prescribed high-dose rosuvastatin (20 or 40 mg daily). Risk was higher with higher rosuvastatin dose.ConclusionsCompared with atorvastatin, rosuvastatin was associated with increased risk of hematuria, proteinuria, and KFRT. Among patients with eGFR <30 ml/min per 1.73 m2, 44% were prescribed a rosuvastatin daily dose exceeding the FDA’s recommended 10 mg daily dose. Our findings suggest the need for greater care in prescribing and monitoring rosuvastatin, particularly in patients who receive high doses or who have severe CKD.

Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?

“…6,7 In the past years, the use of target trial emulation has increased rapidly in the medical literature and also in nephrology research. [8][9][10][11][12][13][14][15] Nevertheless, its concept and advantages may still be unfamiliar and somewhat mysterious to many readers. Furthermore, not every observational study claiming to use "target trial emulation" is applying the framework correctly.…”

Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials

“…We retrieved 3133 unique records, of which 200 were included in the review (Figure 1). All reasons for excluding records after full-text review are given in eAppendix 6 in Supplement 1.…”

“… The included studies spanned 26 fields of medicine, predominately infectious disease (43 [22%]; 27 [14%] on COVID-19), cardiology (30 [15%]), and oncology (30 [15%]) . One hundred and thirty-one studies (66%)…”

Lipidsenkende Therapie bei chronischer Nierenerkrankung im Erwachsenenalter

“…Das seit seiner generischen Verfügbarkeit häufig bevorzugte Rosuvastatin hat Einschränkungen bei der Anwendung bei eingeschränkter Nierenfunktion ( Tab. 1 ), die in einer großen Datenanalyse aus den USA bestärkt wurden 11 . Atorvastatin wäre daher bei CKD das bevorzugte Statin hoher Intensität.…”

“…Das seit seiner generischen Verfügbarkeit häufig bevorzugte Rosuvastatin hat Einschränkungen bei der Anwendung bei eingeschränkter Nierenfunktion (▶ Tab. 1), die in einer großen Datenanalyse aus den USA bestärkt wurden [11] Die Lipoproteinapherese, das heißt die extrakorporale Elimination der Lipoproteine aus dem Blut, stellt die maximale Eskalation der LLT dar und gehört in Deutschland seit dem Jahr 1991 zu den Leistungen der gesetzlichen Krankenversicherung. Seit dem Jahr 2008 werden 3 Indikationen unterschieden: die homozygote familiäre Hypercholesterinämie, die schwere Hypercholesterinämie und die isolierte Lp(a)-Hyperlipoproteinämie (Lp(a) höher als 60 mg/dl mit progredienter ASCVD trotz optimaler Behandlung der vorhandenen kardiovaskulären Risikofaktoren).…”